Knott David M Jr Acquires New Stake in Atyr PHARMA INC (NASDAQ:ATYR)

Knott David M Jr acquired a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 308,133 shares of the company's stock, valued at approximately $1,115,000. Atyr PHARMA makes up about 0.4% of Knott David M Jr's portfolio, making the stock its 28th biggest position. Knott David M Jr owned approximately 0.37% of Atyr PHARMA at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC bought a new stake in shares of Atyr PHARMA during the fourth quarter valued at approximately $3,229,000. JPMorgan Chase & Co. boosted its holdings in shares of Atyr PHARMA by 467.8% during the 4th quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company's stock valued at $646,000 after buying an additional 147,092 shares in the last quarter. American Century Companies Inc. purchased a new stake in shares of Atyr PHARMA in the 4th quarter worth about $319,000. Kingswood Wealth Advisors LLC bought a new position in shares of Atyr PHARMA in the 4th quarter worth about $170,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Atyr PHARMA during the 4th quarter valued at about $144,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Cantor Fitzgerald began coverage on Atyr PHARMA in a research report on Monday, January 6th. They set an "overweight" rating for the company. HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Atyr PHARMA in a report on Friday, March 14th. Finally, Leerink Partners began coverage on Atyr PHARMA in a report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Atyr PHARMA presently has a consensus rating of "Buy" and an average target price of $18.60.

Remove Ads

Atyr PHARMA Stock Down 6.1 %

Shares of Atyr PHARMA stock traded down $0.17 on Friday, reaching $2.62. The company's stock had a trading volume of 1,874,615 shares, compared to its average volume of 873,693. Atyr PHARMA INC has a 52 week low of $1.42 and a 52 week high of $4.66. The firm's fifty day simple moving average is $3.57 and its two-hundred day simple moving average is $3.21. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $232.81 million, a price-to-earnings ratio of -2.79 and a beta of 0.95.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. Equities analysts anticipate that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.